Skip to content
Screener

Halozyme Therapeutics HALO Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$109.2M+8.4%
AMP
Amphastar PharmaceuticalsAMPH
$27.4M—
Opko Health logo
Opko HealthOPK
$44.99M-4.7%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$8.35M+59.3%
Arrowhead Research logo
Arrowhead ResearchARWR
$107.88M-5.6%
TriSalus Life Sciences, Inc. logo
TriSalus Life Sciences, Inc.TLSI
$1.31M-9.2%

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$11.65B+58.3%
Enterprise value$13.66B+54.7%
P/E16.2×-4.6×
P/S7×+0.8×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104
Line itemJune 30,2026December 31,2025
Accrued outsourced manufacturing expenses5,18111,775
Taxes payable26,42644,148
Product returns and sales allowance44,10846,594
Other accrued expenses86,264104,349
Lease liability31,87934,569
Total accrued expenses214,542270,056
Less long-term portion(102,681)(113,863)
Total accrued expenses, current$111,861$156,193

Item 1. Financial Statements

FAQ

What is Halozyme Therapeutics's operating lease liabilities (total)?
Halozyme Therapeutics (HALO) reported operating lease liabilities (total) of $31.88M in Q2 2026.
How has Halozyme Therapeutics's operating lease liabilities (total) changed year-over-year?
Halozyme Therapeutics's operating lease liabilities (total) increased by 10.0% year-over-year, from $28.97M to $31.88M.
What is the long-term trend for Halozyme Therapeutics's operating lease liabilities (total)?
Over 5 years (2020 to 2025), Halozyme Therapeutics's operating lease liabilities (total) has grown at a 48.0% compound annual growth rate (CAGR), from $4.87M to $34.57M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Halozyme Therapeutics's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude